BOSTON, Nov. 26,
2024 /PRNewswire/ -- Elevation Oncology, Inc.
(Nasdaq: ELEV), an innovative oncology company focused on the
discovery and development of selective cancer therapies to treat
patients across a range of solid tumors with significant unmet
medical needs, today announced that Joseph
J. Ferra, President and Chief Executive Officer of Elevation
Oncology, will participate in a fireside chat at the Piper Sandler
36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. ET.
A live webcast and replay of the event will be available on the
Events page of the Company's Investor Relations website at
https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are leveraging our antibody-drug conjugate
(ADC) expertise to advance a novel pipeline, initially targeting
two clinically validated targets in oncology, Claudin 18.2 and
HER3. Our lead candidate, EO-3021, is a potential best-in-class,
Claudin 18.2 ADC and is currently being evaluated in the dose
expansion portion of a Phase 1 trial (NCT05980416) in patients with
advanced, unresectable or metastatic gastric/gastroesophageal
adenocarcinoma that express Claudin 18.2. Additionally, we expect
to nominate a development candidate for our second program, a
HER3-targeting ADC for the treatment of patients with solid tumors
that overexpress HER3, in 2024. For more information, visit
www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Gracie Tong
Senior Director, Investor Relations and Corporate
Communications
gtong@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-302314303.html
SOURCE Elevation Oncology
